1 Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial.

2 Hyperactive Delirium Requires More Aggressive Management in Patients with COVID-19: Temporarily Rethinking "Low and Slow".

3 dopamine, prolactin and treatment of psychoses

4 treatment of early onset schizophrenia: recent trends, challenges and future considerations

5 blonanserin extensively occupies rat dopamine d3 receptors at antipsychotic dose range

6 a randomized-controlled trial with a canadian electronic pill dispenser used to measure and improve medication adherence in patients with schizophrenia

7 pattern of antipsychotic use and its determinants in razi psychiatric hospital

8 rapid, computer vision-enabled murine screening system identifies neuropharmacological potential of two new mechanisms

9 prescribing of psychotropic medications to the elderly population of a canadian province: a retrospective study using administrative databases

10 Characterization of binding of antipsychotics to muscarinic receptors using mouse cerebral cortex.

11 Synthesis, pharmacological evaluation and QSAR study of 6- [3-(4-substituted phenylpiperazin-1-yl)propoxy]benzo[d][1,3] oxathiol-2-ones as potential antipsychotics

12 Is Antipsychotic Treatment Associated With Risk of Pneumonia in People With Serious Mental Illness?: The Roles of Severity of Psychiatric Symptoms and Global Functioning.

13 Effectiveness of a Community-Based Weight Management Program for Patients Taking Antidepressants and/or Antipsychotics.

14 Associations among antipsychotics, metabolism-related diseases, and cataracts in patients with schizophrenia: A retrospective cohort study.

15 Determination of antipsychotic drugs in oral fluid using dried saliva spots by gas chromatography-tandem mass spectrometry.

16 Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease.

17 Bridging Community Mental Health and Primary Care to Improve Medication Monitoring and Outcomes for Patients With Mental Illness Taking Second-Generation Antipsychotics-HDC/DFMC Bridge Project, Phase 1: Group Concept Mapping.

18 Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: Findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey.

19 Focused Ethnographic Examination of Barriers to Use of Long-Acting Injectable Antipsychotics.

20 Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study.

21 Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring

22 Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.

23 Improved Prescriber Adherence to Guidelines on Antipsychotic Medication Management Through Increased Access to Metabolic Monitoring Forms.

24 Antipsychotic Drug Treatment in First-Episode Mania: A 6-Month Longitudinal Study

25 Using Long-Acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia

26 Sleep Apnea Associated With Antipsychotic-Induced Obesity

27 Dissociation in Pharmacokinetic Attenuation Between Central Dopamine D2 Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics: A Systematic Review

28 a double-blind comparison of the effect of the antipsychotics haloperidol and olanzapine on sleep in mania

29 weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studies

30 use of antipsychotics and tardive dyskinesia

31 decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia

32 systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia

33 long-acting injectable antipsychotics in first-episode schizophrenia

34 effects of antipsychotic administration on brain glutamate in schizophrenia: a systematic review of longitudinal 1h-mrs studies

35 antipsychotic treatments; focus on lurasidone

36 impulsivity and novel object recognition test of rat model for vascular cognitive impairment after antipsychotics treatment

37 atypical antipsychotic-induced parkinsonism: a patient case with cyp enzyme implications

38 the efficacy and safety of antipsychotic medications in the treatment of psychosis in patients with parkinson’s disease

39 geographic distribution of antipsychotic use in medicare part d patients

40 lipid profile in antipsychotic drug users: a comparative study

41 direct and indirect drug design approaches for the development of novel tricyclic antipsychotics: potential 5-ht2a antagonist

42 effects of antipsychotics on dentate gyrus stem cell proliferation and survival in animal models: a critical update

43 recovery of behavioral changes and compromised white matter in c57bl/6 mice exposed to cuprizone: effects of antipsychotic drugs

44 serum substance p levels in patients with chronic schizophrenia treated with typical or atypical antipsychotics

45 glycosylated hemoglobin as a screening test for hyperglycemia in antipsychotic-treated patients: a follow-up study

46 temporomandibular disorders in patients with schizophrenia using antipsychotic agents: a discussion paper

47 mitragyna speciosa leaf extract exhibits antipsychotic-like effect with the potential to alleviate positive and negative symptoms of psychosis in mice

48 managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach

49 Introduction: Cardiovascular and Metabolic Risks Associated With Schizophrenia and Antipsychotic Drug Treatment

50 Mechanisms and Risks of Electrocardiographic QT Interval Prolongation When Using Antipsychotic Drugs

51 Assessing Cardiovascular Risks Versus Clinical Benefits of Atypical Antipsychotic Drug Treatment

52 A Case of Atypical Antipsychotic-Induced Somnambulism: A Class Effect

53 Managing Weight Gain and Metabolic Issues in Patients Treated With Atypical Antipsychotics

54 Using Long-Acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia

55 Antipsychotic-induced Hyperprolactinemia in aging populations: Prevalence, implications, prevention and management

56 A Review of Sensitivity and Tolerability of Antipsychotics in Patients With Bipolar Disorder or Schizophrenia: Focus on Somnolence

57 Sexual Dysfunction in Patients Treated With Atypical Antipsychotics

58 The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review

59 Overestimating the Prevalence of Subtherapeutic Dosing of Atypical Antipsychotics

60 Comparing the Use and Discontinuation of Antipsychotics in Clinical Practice: An Observational Study

61 Fibre density and fibre-bundle cross-section of the corticospinal tract are distinctly linked to psychosis-specific symptoms in antipsychotic-naïve patients with first-episode schizophrenia.

62 Cerebral blood flow in striatum is increased by partial dopamine agonism in initially antipsychotic-naïve patients with psychosis.

63 From crisis to control: The role of long-acting injectable antipsychotics in reducing psychiatric service use in bipolar disorder

Keyword Connections

Journals

Research Groups

Bibliographies